Skip to content

DR. VANLERBERGHE LEEN

Active Private limited companyfounded 2011active for 15 yearsBerlaarsesteenweg 87, 2500 LierKBO/BCE: BE 0837.484.439

Lifetime

14 annual accounts with figures on one time axis
peak of €264,024 in 2017
€211,193▲ 2.9%
peak of €151,358 in 2018
€146,458▲ 13.2%
peak of €1.1m in 2020
€799,520▲ 4.8%
€231,084▼ 9.7%
Board2 names since 2011
2 directors and 1 other
Documentsfilings and deeds
29-06-202632 days before the deadline
2025micro format
Dividend €110,000

Key points

from the 2025 annual accounts

Equity

€799,520 ▲ 4.8%
763,0612024+146,458Profit-110,000Dividend799,5202025

DR. VANLERBERGHE LEEN paid out €110,000 in dividends. That is 75% of the 2025 profit.

Filings

14 annual accounts since 2012
AprilJune31 JulyOctober201520202025

The last five annual accounts were filed 23 to 32 days before the end of the period.

Position in the sector

€799,520

More equity than 90% of companies in human health. Sector median €125,088 · 21,349 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 17,816 companies had the same profile as DR. VANLERBERGHE LEEN has now. Each dot stands for 45 companies, two years later.

96.5%
were still trading
3.2%
stopped another way
0.3%
went bankrupt
  • Small
  • 10 to 20 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 497,965 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 17,816 companies, not a prediction for DR. VANLERBERGHE LEEN. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Manager
Director
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0837484439
changes role from manager to director Director discharge: (manager) · General meeting of 03-11-2022 · Gazette deed
reappointed as director General meeting of 08-06-2021 · Gazette deed
Registered office moved from Bevel to Lier The registered office moved from Bevel-Dorp 110, 2560 Bevel to Berlaarsesteenweg 87, bus 2, 2500 Lier · General meeting of 17-01-2012 · Gazette deed
All 25 events

Comparable companies

same main activity, similar in size and age
Company
DR. VANLERBERGHE LEEN Lier €1.0m €211,193 77.6% -
Dr. Marc Claessens Schilde €1.1m €212,787 65.9% -
DR. LIES VAN RANSBEECK Brecht €1.1m €224,258 96.7% -
DR. PIETER DEBAENST Antwerp €1.2m €206,930 80.1% -
Dr. Lechkar-Reumatologie Antwerp €0.9m €223,083 93.4% -
NIOTHO Edegem €1.0m €182,040 76.6% -
DOKTEUR DE BIE Rixensart €1.0m €220,021 28.1% -

These companies have the same main activity as DR. VANLERBERGHE LEEN: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €911,000 and €1.2m, founded between 2010 and 2011.

Official details

Source: KBO
Status
Active since 23-06-2011Normal situation
Activity
Specialist medical practiceNACE 86220
Establishment unit
2.201.532.3882500 Lier, registered on 23-06-2011
Financial year end
31 December
Peppol
Reachable since 02-12-2025
Company details

Annual accounts 2025

≈ €390,000estimated
€1.0m▲ 1.2%
Filing
Filed on 29-06-2026, 32 days before the end of the filing period
Financials

Insights on DR. VANLERBERGHE LEEN

DR. VANLERBERGHE LEEN files the micro format. That format states no turnover. The gross margin rose from €172,849 in 2012 to €211,193 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about DR. VANLERBERGHE LEEN

What is the company number of DR. VANLERBERGHE LEEN?
The company number of DR. VANLERBERGHE LEEN is 0837.484.439. The VAT number is the same number with BE in front: BE 0837.484.439.
Where is DR. VANLERBERGHE LEEN based?
The registered office is at Berlaarsesteenweg 87, 2500 Lier.Company details
What does DR. VANLERBERGHE LEEN do?
According to the KBO register, the main activity is specialist medical practice (NACE 86220).
What is the legal form of DR. VANLERBERGHE LEEN?
DR. VANLERBERGHE LEEN is a private limited company (BV).
When was DR. VANLERBERGHE LEEN founded?
DR. VANLERBERGHE LEEN was founded on 23-06-2011.
Is DR. VANLERBERGHE LEEN still active?
Yes, DR. VANLERBERGHE LEEN is an active enterprise in the KBO register.
What is the turnover of DR. VANLERBERGHE LEEN?
The turnover in financial year 2025 is ≈ €390,000. This figure is estimated from the gross margin of €211,193 and 40 comparable companies (NACE 86220). It probably lies between €330,000 and €520,000.Financials
Is DR. VANLERBERGHE LEEN profitable?
In financial year 2025, DR. VANLERBERGHE LEEN made a profit of €146,458.
Where can I find the annual accounts of DR. VANLERBERGHE LEEN?
DR. VANLERBERGHE LEEN filed 14 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of DR. VANLERBERGHE LEEN due?
DR. VANLERBERGHE LEEN must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.